ABBV
AbbVie’s quiet second act
AbbVie has been trying to prove it’s more than a one-drug story, and neuroscience is increasingly the supporting character that’s stealing scenes. Management now expects the business to generate $12.7 billion in sales this year, which is a pretty loud way of saying the brain-drug portfolio is no side hustle anymore.
Why investors should care
That matters because AbbVie is still in the middle of its post-Humira identity makeover. If neuroscience keeps growing like this, it gives the company a sturdier cushion against patent pressure, pipeline hiccups, and the usual pharma drama that makes investors reach for antacids.
The bigger read-through
What’s interesting here is the mix: not just one shiny approval, but a franchise that’s starting to look like an actual engine. In pharma-speak, that’s what you want — multiple growth legs instead of a single pogo stick.
- More sales from neuroscience means more diversification.
- More diversification means less dependence on legacy revenue streams.
- Less dependence on legacy revenue streams means Wall Street can squint a little less at AbbVie’s future.
Big picture: AbbVie is trying to turn “former Humira giant” into “company with a real next act,” and neuroscience may be the part of the script that finally sticks.